CASI Pharmaceuticals (CASI) director James Huang reports initial holdings

Rhea-AI Filing Summary

CASI Pharmaceuticals director James Huang filed a Form 3 reporting his initial ownership position. The filing lists three fully vested stock option awards over CASI ordinary shares: options over 10,000 shares at an exercise price of $1.69 expiring on October 1, 2035, 10,000 shares at $2.69 expiring on May 1, 2033, and 101,571 shares at $1.93 expiring on March 20, 2026. It also reports indirect ownership of 4,529,956 ordinary shares held by Panacea Venture Healthcare Fund II, L.P., an entity associated with Huang. He may be deemed to share beneficial ownership of these shares but explicitly disclaims such beneficial ownership.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Huang James

(Last) (First) (Middle)

C/O PANACEA VENTURE

NO. 5, LANE 1350, FUXING MIDDLE ROAD

(Street)

SHANGHAI 200031

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
CASI Pharmaceuticals, Inc. [ CASI ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	4,529,956	I	See Footnote(1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	(2)	10/01/2035	Ordinary Shares	10,000	$1.69	D
Stock Option	(2)	05/01/2033	Ordinary Shares	10,000	$2.69	D
Stock Option	(2)	03/20/2026	Ordinary Shares	101,571	$1.93	D

Explanation of Responses:

1. Panacea Venture Healthcare Fund II, L.P. is the record holder of the Ordinary Shares reported herein. James Huang is the sole owner of Panacea Innovation Limited, which is the sole owner of Panacea Venture Healthcare Fund II GP Company, Ltd., which is the general partner of Panacea Venture Healthcare Fund II, L.P. As a result, James Huang may be deemed to share beneficial ownership of the Ordinary Shares reported herein, but disclaims such beneficial ownership.

2. The stock option is fully vested and exercisable.

	/s/ James Huang	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the CASI (CASI) Form 3 filed by James Huang report?

The Form 3 reports James Huang’s initial ownership in CASI Pharmaceuticals. It shows several fully vested stock options and a large indirect holding of 4,529,956 ordinary shares through Panacea Venture Healthcare Fund II, L.P., for which he disclaims beneficial ownership.

How many CASI stock options does James Huang hold according to the Form 3?

James Huang holds three option positions over CASI ordinary shares. They cover 10,000 shares at $1.69, 10,000 shares at $2.69, and 101,571 shares at $1.93, each fully vested and exercisable with expiration dates ranging from 2026 to 2035.

What indirect CASI share ownership is associated with James Huang?

The filing reports 4,529,956 CASI ordinary shares held by Panacea Venture Healthcare Fund II, L.P. James Huang is associated with the fund’s control structure and may be deemed to share beneficial ownership, but he formally disclaims such beneficial ownership in the filing.

Are James Huang’s CASI stock options already vested and exercisable?

Yes. The footnotes state that each reported CASI stock option is fully vested and exercisable. This means Huang can convert those options into ordinary shares at the stated exercise prices any time before their respective expiration dates, subject to applicable rules.

Does the CASI Form 3 show any recent insider buying or selling by James Huang?

No specific insider purchases or sales are identified. The Form 3 functions as an initial ownership report, listing existing stock options and indirect share holdings, rather than documenting new buy or sell transactions in CASI Pharmaceuticals shares.